IP Library Granted Patent US 10,093,933
Granted Patent B2
US 10,093,933 · App. 15/112,739 · Granted Oct 9, 2018

Compositions and methods for detecting microorganisms

Inventors: Urs A. Ochsner (Boulder, CO); Nebojsa Janjic (Boulder, CO)
Assignee: SOMALOGIC, INC.
C12N15/115C12N15/1048C12Q1/14G01N33/5308G01N33/569C12N2310/16G01N2333/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,093,933
App. No.
15/112,739
Granted
Oct 9, 2018
Kind
B2
Abstract

Described herein are compositions and methods for detecting the presence or absence of a microorganism in a sample comprising contacting the sample with an aptamer capable of binding to a cell-surface protein of the microorganism to form a complex, contacting the mixture with a second aptamer capable of binding to the first cell-surface protein or a second cell-surface protein of the microorganism; and performing an assay to detect the second aptamer, wherein detecting the second aptamer indicates that the microorganism is present in the sample, and wherein not detecting the second aptamer indicates that the microorganism is absent from the sample.

Claims (7)

1. A nucleic acid molecule comprising the sequence of GGCWWCGGGWACCWAWWAWNGGWWWAGCC(N) n GWC (SEQ ID NO:14), wherein W is independently, for each occurrence, a C-5 modified pyrimidine, N is any unmodified or modified nucleotide, and n is 0, 1, 2, 3, 4 or 5, wherein the nucleic acid molecule is from about 32 to about 100 nucleotides in length.

2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is at least about 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides in length.

3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs:1-8, wherein W is a C-5 modified pyrimidine.

4. The nucleic acid molecule of claim 1 , wherein the C-5 modified pyrimidine is selected from the group consisting of 5-(N-benzylcarboxyamide)-2′-deoxycytidine (BndC); 5-(N-2-phenylethylcarboxyamide)-2′-deoxycytidine (PEdC); 5-(N-3-phenylpropylcarboxyamide)-2′-deoxycytidine (PPdC); 5-(N-1-naphthylmethylcarboxyamide)-2′-deoxycytidine (NapdC); 5-(N-2-naphthylmethylcarboxyamide)-2′-deoxycytidine (2NapdC); 5-(N-1-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (NEdC); 5-(N-2-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (2NEdC); 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU); 5-(N-isobutylcarboxyamide)-2′-deoxyuridine (iBudU); 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU); 5-(N-[1-(3-trimethylammonium)propyl]carboxyamide)-2′-deoxyuridine chloride and 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU).

5. The nucleic acid molecule of claim 1 , wherein C-5 modified pyrimidine is a 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU).

6. The nucleic acid molecule of claim 3 , wherein the C-5 modified pyrimidine is selected from the group consisting of 5-(N-benzylcarboxyamide)-2′-deoxycytidine (BndC); 5-(N-2-phenylethylcarboxyamide)-2′-deoxycytidine (PEdC); 5-(N-3-phenylpropylcarboxyamide)-2′-deoxycytidine (PPdC); 5-(N-1-naphthylmethylcarboxyamide)-2′-deoxycytidine (NapdC); 5-(N-2-naphthylmethylcarboxyamide)-2′-deoxycytidine (2NapdC); 5-(N-1-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (NEdC); 5-(N-2-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (2NEdC); 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU); 5-(N-isobutylcarboxyamide)-2′-deoxyuridine (iBudU); 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU); 5-(N-[1-(3-trimethylammonium)propyl]carboxyamide)-2′-deoxyuridine chloride and 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU).

7. The nucleic acid molecule of claim 3 , wherein C-5 modified pyrimidine is a 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU).

Assignments (3)
CHANGE OF NAME Recorded Feb 4, 2022
From: SOMALOGIC INC.
To: SOMALOGIC OPERATING CO. INC.
Reel/Frame 058885/0983 →
RELEASE OF SECURITY INTEREST Recorded Apr 20, 2021
From: MADRYN HEALTH PARTNERS, LP, FORMERLY VISIUM HEALTHCARE PARTNERS, LP
To: SOMALOGIC, INC.
Reel/Frame 055981/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2016
From: OCHSNER, URS A.; JANJIC, NEBOJSA
To: SOMALOGIC, INC.
Reel/Frame 039202/0140 →
Continuity (3)
Provisional Application 61940955 · Feb 18, 2014
Provisional Application 61947627 · Mar 4, 2014
Related Publication 20160348112A1 · Dec 1, 2016